|
|
GOSPEL 2 – la colchicine dans le traitement de la crise de goutte en France – analyse d’un sous-groupe de l’étude GOSPEL. Doses utilisées en pratique courante sans considération de l’insuffisance rénale et de l’âge
Tristan Pascart
,
Sylvie Lancrenon
,
Sabine Lanz
,
Catherine Delva
,
Pascal Guggenbuhl
et al.
Journal articles
hal-01630464v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
GOSPEL 2 – Colchicine for the treatment of gout flares in France – a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age
Tristan Pascart
,
Sylvie Lancrenon
,
Sabine Lanz
,
Catherine Delva
,
Pascal Guggenbuhl
et al.
Journal articles
hal-01282350v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Reply to the comment of Mathieu et al., "American guidelines for the management of gout as seen by general practitioners
Julia Goossens
,
Sylvie Lancrenon
,
Sabine Lanz
,
Hang-Korng Ea
,
Charles Lambert
et al.
Journal articles
hal-01903475v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
Julia Goossens
,
Sylvie Lancrenon
,
Sabine Lanz
,
Hang-Korng Ea
,
Charles Lambert
et al.
Journal articles
hal-01528712v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|